Curis Registers Resale of 33.3M Shares From October Private Placement
CRIS sits 37% above its 52-week low of $0.325 on light trading volume (0.2× avg).
Summary
Curis filed the S-3 covering resale of 33,333,360 shares from its October 2026 private placement — 2.6M outstanding shares plus 30.8M warrant shares — with no new proceeds to the company from the resale.
Key Events · Financing and Capital Events · CRIS
-
Resale Registration Covers 33.3M Shares
The S-3 registers 33,333,360 shares for resale: 2,574,517 outstanding shares, 14,092,163 pre-funded warrant shares and 16,666,680 common warrant shares from the October 2026 private placement.
-
Warrant Terms Set the Supply Timeline
Pre-funded warrants carry a $0.01 strike and are exercisable immediately; common warrants carry a $0.60 strike, become exercisable April 19, 2027 and expire April 19, 2032.
-
No Proceeds From the Resale
Curis receives nothing from selling-stockholder sales; it only collects cash if the October 2026 Warrants are exercised for cash.
-
Overhang Against a Small Share Base
The 14,092,163 pre-funded warrant shares are exercisable now against 6,679,229 shares outstanding as of October 20, 2026 — roughly twice the current share count in near-term supply.
Analysis · CRIS · Life Sciences
This S-3 makes the October 2026 private placement resellable: 33,333,360 shares, of which only 2,574,517 are already outstanding and the rest sit behind warrants. The overhang is real but partly deferred — the 16,666,680 common warrants cannot be exercised until April 19, 2027 at $0.60, while the 14,092,163 pre-funded warrants at $0.01 are exercisable now and are the near-term supply. Against 6,679,229 shares outstanding as of October 20, 2026, the pre-funded warrants alone are roughly twice the current share count, so the float can expand sharply if holders convert and sell. Curis gets no proceeds from the resale itself, only from any cash warrant exercise. The backdrop is severe: a Nasdaq delisting determination on November 2, 2026, a going-concern warning in the Q3 10-Q, and a November 18, 2026 shareholder vote on a reverse split. The filing is a contractual obligation under the registration rights agreement, not a new capital raise.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.33 to $28.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.